


## Data Sheet

<b>Product Name:</b>	UNC0224
<b>Cat. No.:</b>	CS-2210
<b>CAS No.:</b>	1197196-48-7
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>43</sub> N <sub>7</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	485.67
<b>Target:</b>	Histone Methyltransferase
<b>Pathway:</b>	Epigenetics
<b>Solubility:</b>	DMSO : 16.67 mg/mL (34.32 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

UNC0224 is a potent and selective G9a inhibitor with IC<sub>50</sub> of 15 nM in the G9a Thioglo assay. IC<sub>50</sub> value: 15 nM [1] Target: G9a  
UNC0224 (Compound 8) also potently inhibited GLP with an IC<sub>50</sub> of 20 nM and 58 nM in the Thioglo assay and and AlphaScreen, respectively. 8 was more than 1000-fold selective for G9a over SET7/9 (a H3K4 HMT) and SET8/PreSET7 (a H4K20 HMT) in Thioglo-based biochemical assays [1] [2].

### PROTOCOL (Extracted from published papers and Only for reference)

Enzyme assay [1] Histone methyltransferase assay was performed using a coupled assay (Collazo et al. 2005). In this assay SAHH (S-adenosylhomocysteine hydrolase) and adenosine deaminase convert the methyltransferase reaction product (S-adenosylhomocysteine) to homocysteine and inosine. Homocysteine can be quantified using Thioglo (Calbiochem). Substrate peptide used in this assay was the first 25 residues of histone 3 [H3 (1-25)]. SAHH clone was provided by Dr. Trievel, University of Michigan. For IC<sub>50</sub> determination, assay mixtures were prepared with 5 μM SAHH, about 0.3 U/mL of adenosine deaminase from Sigma, 16 μM SAM, 25 nM G9a and 15 μM Thioglo. UNC0224 was added at concentrations ranging from 6 nM to 25 μM. After 5 min incubation, reactions were initiated by the addition of 5 μM H3 (1-25) peptide. The methylation reaction was followed by monitoring the increase in fluorescence using BioTek Synergy2 plate reader with 360/40 nm excitation filter and 528/20 nm emission filter for 20 min in 384 well-plate format. Homocysteine generated in the assay was quantitated using standard curves. Activity values were corrected by subtracting background caused by the peptide and the protein. IC<sub>50</sub> values were calculated using four parameter logistic equation by Sigmaplot software. Standard deviations were calculated from two independent xperiments.

### References:

- [1]. Liu F, et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem. 2009 Dec 24;52(24):7950-3.
- [2]. Liu F, et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem. 2010 Aug 12;53(15):5844-57.

### CAIndexNames:

4-Quinazolinamine, 7-[3-(dimethylamino)propoxy]-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6-methoxy-N-(1-methyl-4-piperidinyl)-

### SMILES:

CN1CCC(NC2=C3C=C(OC)C(OCCCN(C)C)=CC3=NC(N4CCN(C)CCC4)=N2)CC1

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA